Sompo Asset Management Co. Ltd. Sells 130 Shares of Zoetis Inc. (NYSE:ZTS)

Sompo Asset Management Co. Ltd. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,250 shares of the company’s stock after selling 130 shares during the quarter. Sompo Asset Management Co. Ltd.’s holdings in Zoetis were worth $910,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Webster Bank N. A. grew its position in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $40,000. LRI Investments LLC bought a new stake in shares of Zoetis during the first quarter valued at approximately $43,000. Hazlett Burt & Watson Inc. boosted its position in shares of Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC bought a new stake in shares of Zoetis during the second quarter valued at approximately $49,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Trading Down 0.3 %

Zoetis stock opened at $192.73 on Friday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The business’s fifty day simple moving average is $184.70 and its two-hundred day simple moving average is $174.47. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $87.94 billion, a price-to-earnings ratio of 37.13, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the business earned $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.